Definitions for glycomimetics
gly·comimet·ics

WikidataRate this definition:0.0 / 0 votes

1. GlycoMimetics

   The mission of GlycoMimetics, Inc. ("GMI") is to develop novel small molecule therapeutics using a specialized platform technology based upon the roles that carbohydrates play in important biological processes. The company believes that carbohydrate mimics ("glycomimetic" compounds) represent an important new class of drugs. GMI is positioned to lead this emerging field. The company so far has identified three types of novel and proprietary compounds with potential therapeutic utility. One is a class of anti-inflammatory compounds which have been shown to reduce key measures of inflammation in several animal models; the second is a novel anti-infective which has been shown to reduce virulence of Pseudomonas; the third is a class of biologically active compounds with potential in the treatment or prevention of complications of diabetes or atherosclerosis. GMI has proprietary compounds that inhibit binding of E-, P-, and L-selectin, a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue. Selectin binding has been shown to be involved in most, if not all, disease processes that involve inflammation. A potent pan-selectin inhibitor would have the potential to address many major market opportunities. GMI is currently exploring the potential of its lead pan-selectin inhibitor to treat vaso-occlusive crises of sickle cell disease. The company also plans to explore additional indications that present further opportunities, including myocardial infarction and pulmonary inflammation. GMI has extensive data demonstrating the ability of its proprietary compounds to inhibit selectin binding, both in static assays and under conditions simulating blood flow. In addition, several compounds have been tested in animal models. These have been shown to limit inflammatory cell adhesion and migration and to affect other disease-related endpoints in animal models. A lead compound has recently been selected for this program, and additional testing is underway toward a goal of filing an IND and initiating human clinical trials. A pre-IND meeting with the FDA is expected in May 2007. A second opportunity developed by GMI is to treat or prevent infections caused by Pseudomonas aeruginosa, a bacterium responsible for increasing numbers of infections which are proving refractory to treatment with antibiotics. This is a critical unmet need in a number of patient populations. Cystic fibrosis patients are chronically colonized by Pseudomonas, and the infection is a major cause of morbidity and mortality in these patients. Pseudomonas is also difficult to treat in other patients, including those who develop pneumonia while on ventilators and those who suffer from burns or from urinary tract infections associated with long term catheterization. GMI has developed a proprietary lead compound (GMI-1051) that inhibits key proteins involved in Pseudomonas infection and virulence. Specifically, the compound inhibits bacterial adhesion and limits bacterial cytotoxicity. In pulmonary infections, data suggest that GMI-1051 may also restore ciliary beat which is inhibited by Pseudomonas, thus enhancing clearance. GMI's objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections which have failed to respond to antibiotic treatment. GMI has also identified a third opportunity based upon E-selectin specific antagonists. The company is exploring this approach to developing drug candidates that could be used to treat or prevent complications of diabetes or atherosclerosis. GMI was founded through the acquisition of assets and expertise of a predecessor company, GlycoTech. GlycoTech developed technology to identify and screen carbohydrate mimics initially through a collaboration with Ciba-Geigy (later Novartis), and then independently. In addition, GlycoTech's screening capabilities...

CrunchBaseRate this definition:0.0 / 0 votes

1. GlycoMimetics

   GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.

How to pronounce glycomimetics?

1. Alex

   US English

   David

   US English

   Mark

   US English

   Daniel

   British

   Libby

   British

   Mia

   British

   Karen

   Australian

   Hayley

   Australian

   Natasha

   Australian

   Veena

   Indian

   Priya

   Indian

   Neerja

   Indian

   Zira

   US English

   Oliver

   British

   Wendy

   British

   Fred

   US English

   Tessa

   South African

How to say glycomimetics in sign language?

Numerology

1. Chaldean Numerology

   The numerical value of glycomimetics in Chaldean Numerology is: 6

2. Pythagorean Numerology

   The numerical value of glycomimetics in Pythagorean Numerology is: 9

References

1. ^ Wikidata
   https://www.wikidata.org/w/index.php?search=glycomimetics
2. ^ CrunchBase
   https://www.crunchbase.com/organization/glycomimetics